May 4, 2005 (updated May 5, 2005) — Editor's Note: On April 29, Amylin Pharmaceuticals, Inc., and Eli Lilly and Co. announced that the U.S. Food and Drug Administration (FDA) had approved exenatide ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. In patients with very poorly controlled type 2 diabetes ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. The FDA approved exenatide in April 2005 and it was the ...

Exenatide is a generic prescription drug approved to help manage blood sugar levels in adults with type 2 diabetes. It’s not available in a brand-name version. Exenatide comes as a liquid solution ...

Treatment with the diabetes drug exenatide was associated with a significant decrease in hyperglycemia in acute stroke patients, a new study shows. The research could offer clinicians an alternative ...

SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., March 26 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (NASDAQ: AMLN) , Eli Lilly and Company (NYSE: LLY) and ...

As an adjunct to primary percutaneous coronary intervention (PCI), the experimental agent exenatide is cardioprotective in patients with ST-segment elevation myocardial infarction (STEMI)—but only in ...

Even with treatment, such as combined metformin and sulfonylurea, glycemic control can be compromised in patients with type 2 diabetes. Furthermore, these drugs are associated with weight gain. There ...

Seven years after receiving a kidney transplant, a 44-year old woman with a 31-year history of type 1 diabetes mellitus and long-term complications (retinopathy, neuropathy, and end-stage renal ...

A follow-up study of patients with Parkinson's disease (PD) who participated in an earlier 'proof of concept' clinical trial using exenatide showed that improvements persisted 12 months after ...

A follow-up study of patients with Parkinson’s disease (PD) who participated in an earlier “proof of concept” clinical trial using exenatide showed that improvements persisted twelve months after ...